Free Trial

Alkermes Q1 2024 Earnings Report

Alkermes logo
$30.06 -1.60 (-5.05%)
As of 04:00 PM Eastern

Alkermes EPS Results

Actual EPS
$0.43
Consensus EPS
$0.58
Beat/Miss
Missed by -$0.15
One Year Ago EPS
-$0.10

Alkermes Revenue Results

Actual Revenue
$350.37 million
Expected Revenue
$360.26 million
Beat/Miss
Missed by -$9.89 million
YoY Revenue Growth
+21.80%

Alkermes Announcement Details

Quarter
Q1 2024
Time
Before Market Opens

Conference Call Resources

Remove Ads

Alkermes Earnings Headlines

Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
Alkermes price target raised to $52 from $40 at Deutsche Bank
See More Alkermes Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Alkermes? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alkermes and other key companies, straight to your email.

About Alkermes

Alkermes (NASDAQ:ALKS), a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

View Alkermes Profile

More Earnings Resources from MarketBeat